<html xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type  content="text/html; charset=UTF-8" ><meta name=ProgId  content=Word.Document ><meta name=Generator  content="Microsoft Word 14" ><meta name=Originator  content="Microsoft Word 14" ><link rel=File-List  href="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/filelist.xml" ><title></title><!--[if gte mso 9]><xml><o:DocumentProperties><o:Author>DAVE</o:Author><o:LastAuthor>独自1388757202</o:LastAuthor><o:Revision>1</o:Revision><o:Pages>10</o:Pages><o:Characters>15371</o:Characters><o:Lines>119</o:Lines><o:Paragraphs>33</o:Paragraphs></o:DocumentProperties><o:CustomDocumentProperties><o:KSOProductBuildVer dt:dt="string" >2052-12.1.0.18608</o:KSOProductBuildVer><o:ICV dt:dt="string" >078E8424DDD24F78905C8F0E629D632B_13</o:ICV></o:CustomDocumentProperties></xml><![endif]--><!--[if gte mso 9]><xml><o:OfficeDocumentSettings></o:OfficeDocumentSettings></xml><![endif]--><!--[if gte mso 9]><xml><w:WordDocument><w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel><w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery><w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery><w:DocumentKind>DocumentNotSpecified</w:DocumentKind><w:DrawingGridVerticalSpacing>7.8 磅</w:DrawingGridVerticalSpacing><w:PunctuationKerning></w:PunctuationKerning><w:View>Web</w:View><w:Compatibility><w:AdjustLineHeightInTable/><w:DontGrowAutofit/><w:BalanceSingleByteDoubleByteWidth/><w:DoNotExpandShiftReturn/><w:UseFELayout/></w:Compatibility><w:Zoom>0</w:Zoom></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml><w:LatentStyles DefLockedState="false"  DefUnhideWhenUsed="true"  DefSemiHidden="true"  DefQFormat="false"  DefPriority="99"  LatentStyleCount="260" >
<w:LsdException Locked="false"  Priority="0"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Normal" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="heading 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Normal Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="footnote text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="annotation text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="header" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="footer" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="35"  SemiHidden="false"  QFormat="true"  Name="caption" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="table of figures" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="envelope address" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="envelope return" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="footnote reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="annotation reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="line number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="page number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="endnote reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="endnote text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="table of authorities" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="macro" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="toa heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="10"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Title" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Closing" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Signature" ></w:LsdException>
<w:LsdException Locked="false"  Priority="1"  SemiHidden="false"  Name="Default Paragraph Font" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Message Header" ></w:LsdException>
<w:LsdException Locked="false"  Priority="11"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Subtitle" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Salutation" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Date" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text First Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text First Indent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Note Heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Block Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="Hyperlink" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="FollowedHyperlink" ></w:LsdException>
<w:LsdException Locked="false"  Priority="22"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Strong" ></w:LsdException>
<w:LsdException Locked="false"  Priority="20"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Emphasis" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Document Map" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Plain Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="E-mail Signature" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="Normal (Web)" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Acronym" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Address" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Cite" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Code" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Definition" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Keyboard" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Preformatted" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Sample" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Typewriter" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Variable" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Normal Table" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="annotation subject" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="No List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="1 / a / i" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="1 / 1.1 / 1.1.1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Article / Section" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Contemporary" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Elegant" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Professional" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Subtle 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Subtle 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Balloon Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Table Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Theme" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Placeholder Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="No Spacing" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Paragraph" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Quote" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Intense Quote" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 6" ></w:LsdException>
</w:LatentStyles></xml><![endif]--><style>
@font-face{
font-family:"Times New Roman";
}

@font-face{
font-family:"宋体";
}

@font-face{
font-family:"等线";
}

@font-face{
font-family:"Wingdings";
}

@font-face{
font-family:"Arial Narrow";
}

@font-face{
font-family:"微软雅黑";
}

p.MsoNormal{
mso-style-name:正文;
mso-style-parent:"";
margin:0pt;
margin-bottom:.0001pt;
mso-pagination:none;
text-align:justify;
text-justify:inter-ideograph;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

span.10{
font-family:'Times New Roman';
}

span.15{
font-family:'Times New Roman';
font-size:9.0000pt;
}

span.16{
font-family:'Times New Roman';
color:rgb(5,99,193);
text-decoration:underline;
text-underline:single;
}

span.17{
font-family:'Times New Roman';
font-size:9.0000pt;
}

p.p{
mso-style-name:"普通\(网站\)";
mso-style-noshow:yes;
margin-top:5.0000pt;
margin-bottom:5.0000pt;
mso-margin-top-alt:auto;
mso-margin-bottom-alt:auto;
mso-pagination:widow-orphan;
text-align:left;
font-family:宋体;
font-size:12.0000pt;
}

p.MsoFooter{
mso-style-name:页脚;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
layout-grid-mode:char;
mso-pagination:none;
text-align:left;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

p.MsoHeader{
mso-style-name:页眉;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
border-bottom:1.0000pt solid windowtext;
mso-border-bottom-alt:0.7500pt solid windowtext;
padding:0pt 0pt 1pt 0pt ;
layout-grid-mode:char;
mso-pagination:none;
text-align:center;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

span.msoIns{
mso-style-type:export-only;
mso-style-name:"";
text-decoration:underline;
text-underline:single;
color:blue;
}

span.msoDel{
mso-style-type:export-only;
mso-style-name:"";
text-decoration:line-through;
color:red;
}

table.MsoNormalTable{
mso-style-name:普通表格;
mso-style-parent:"";
mso-style-noshow:yes;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-padding-alt:0.0000pt 5.4000pt 0.0000pt 5.4000pt;
mso-para-margin:0pt;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-family:'Times New Roman';
font-size:10.0000pt;
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;
}
@page{mso-page-border-surround-header:no;
	mso-page-border-surround-footer:no;}@page Section0{
margin-top:72.0000pt;
margin-bottom:72.0000pt;
margin-left:89.8500pt;
margin-right:89.8500pt;
size:595.3000pt 841.9000pt;
layout-grid:15.6000pt;
mso-header-margin:42.5500pt;
mso-footer-margin:28.3500pt;
mso-footer:url("5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap%20MS结合网络药理学分析的综合策略0326.files/header.html") f0;
}
div.Section0{page:Section0;}@page Section1{
margin-top:72.0000pt;
margin-bottom:72.0000pt;
margin-left:89.8500pt;
margin-right:89.8500pt;
size:595.3000pt 841.9000pt;
layout-grid:15.6000pt;
mso-header-margin:42.5500pt;
mso-footer-margin:49.6000pt;
mso-header:url("5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap%20MS结合网络药理学分析的综合策略0326.files/header.html") h1;
mso-footer:url("5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap%20MS结合网络药理学分析的综合策略0326.files/header.html") f1;
}
div.Section1{page:Section1;}</style></head><body style="tab-interval:21pt;text-justify-trim:punctuation;" ><!--StartFragment--><div class="Section0"  style="layout-grid:15.6000pt;" ><p class=p  align=center  style="text-align:center;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:20.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中药消癖颗粒代谢产物分析：基于</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:20.0000pt;mso-font-kerning:1.0000pt;" >UPLC-Q-Orbitrap MS结合网络药理学分析的</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:20.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >综合策略</font></span><b style="mso-bidi-font-weight:normal" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
mso-ansi-font-weight:bold;font-size:18.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=p  align=center  style="text-indent:24.1000pt;text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >王能</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b，1</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，杨博文</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b，1</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，张菊萍</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，郑轶枫</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，王胜奇</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，张晓彤</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，司徒红林</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，林毅</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b，*</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >,</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >王志宇</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >a，b，*</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="text-indent:24.0000pt;text-align:center;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >DOI: </span><span><a href="https://doi.org/10.1016/j.biopha.2019.109569" ><u><span class="16"  style="mso-spacerun:'yes';font-family:宋体;text-decoration:underline;
text-underline:single;" >https://doi.org/10.1016/j.biopha.2019.109569</span></u></a></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="text-indent:24.0000pt;text-align:center;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >Biomedicine & Pharmacotherapy ( IF 6.529 )</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="text-align:justify;text-justify:inter-ideograph;line-height:150%;" ><b style="mso-bidi-font-weight:normal" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
mso-ansi-font-weight:bold;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >关键词：</font></span></b><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒、超高效液相色谱－四极杆</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/静电场轨道阱高分辨质谱</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、网络药理学、胆汁酸代谢</font></span><b style="mso-bidi-font-weight:normal" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
mso-ansi-font-weight:bold;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >摘要</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒已获国家药品监督管理局批准用于治疗乳腺增生症。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >然而，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的吸收物质及其对代谢途径的影响在很大程度上仍是未知的。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >采用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >液相色谱与质谱联用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >技术</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >鉴定血清中存在的物质。</font> </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >利用网络药理学来探索所涉及的潜在代谢靶标和</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >代谢</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >途径。进行蛋白质印迹</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >法</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和免疫荧光测定</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >以进行</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >靶标验证。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >外源性结果表明</font>196种化合物被过滤为吸收物质，其中在大鼠血清中初步鉴定出63种成分或代谢物，发现丹参酮II和丹参酮I的代谢物作为主要代谢途径。随后，内源性结果显示，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >可</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >显著</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >调节血清生化指标，胆汁酸分泌信号</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >通路</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在所有</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >调控</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >途径中排名第一。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >通过消癖颗粒治疗</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >后</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >胆酸</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、甘氨胆酸、牛磺鹅脱氧胆酸和牛磺胆酸等中间体的水平显著上调，伴随关键酶</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CYP7A1的表达增加，表明</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >可加速胆汁酸代谢途径。我们的研究首次展示了</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒在体内的综合代谢情况，胆汁酸合成途径可能是促成该药实现药理功能的关键机制之一。</font></span></p></div>
<span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><br clear=all style='page-break-before:always;mso-break-type:section-break'></span>
<div class="Section1"  style="layout-grid:15.6000pt;" ><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >缩写：</font><font face="宋体" >EBE，淫羊藿；CD，肉苁蓉；LH，益母草；SM，丹参；CA, 郁金；RC, 莪术；LL，女贞子；RPM，何首乌；CG，牡蛎；CT，鳖甲；TAM，肿瘤相关巨噬细胞；T</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >CM</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，中医药；</font><font face="宋体" >LC-MS，高效液相色谱与质谱联用；UPLC，超高效液相色谱；MS，质谱；POS，正离子；NEG，负离子；VIP，变量重要性指标；PCA，主成分分析；KEGG，京都基因和基因组百科全书；CYP7A1，胆固醇 7α-羟化酶；&#9651;M，分子质量的变化；SD，斯普拉格-杜勒鼠；IDA，信息依赖基础；TIC，总离子色谱图；SDS-PAGE，十二烷基硫酸钠聚丙烯酰胺凝胶电泳；DAP</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >I</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >4&#8242;,6</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >&nbsp;<font face="宋体" >-二脒基-2-苯基吲哚。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >1.</font><font face="宋体" >介绍</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒是由</font><font face="宋体" >1</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >种草药组成的中药方剂，包括淫羊藿（</font><font face="宋体" >E</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >B</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名淫羊藿）、肉苁蓉（</font><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >D</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名肉苁蓉）、益母草（</font><font face="宋体" >L</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >H</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名益母草）、丹参（</font><font face="宋体" >S</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >M</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名丹参）、郁金（</font><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >A</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名郁金）、莪术（</font><font face="宋体" >R</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >C</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名莪术）、女贞子（</font><font face="宋体" >L</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >L</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名女贞子）、制首乌（</font><font face="宋体" >R</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >PM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名制首乌）、牡蛎（</font><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >G</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名牡蛎）、鳖甲（</font><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >T</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中文名鳖甲）</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。此前，研究发现该配方可显著抑制动物乳腺增生模型中雌激素和黄体生成素的表达水平</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >2，3】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。更重要的是，消癖颗粒可以阻断</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2,2-二羟甲基丁酸</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font><font face="宋体" >D</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MBA</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >）诱导的乳腺癌异种移植物中的致癌作用</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >4】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >同时，我们之前也报道了该配方可以通过靶向</font><font face="宋体" >MMTV-PyVT</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >+/-</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >小鼠自发性乳腺癌模型上的肿瘤相关巨噬细胞（</font><font face="宋体" >TAMs）/CXCL1通路来预防乳腺癌的发生和转移</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >5】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。目前，该配方已被中国国家药品监督管理局批准用于治疗乳腺增生。淫羊藿苷和丹参酮分别是</font><font face="宋体" >EB和SM中存在的主要化合物，因此被认为是配方质量控制的主要标准。化学分析表明，不同批次配方中淫羊藿苷浓度测定在2.977</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >-</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >3.067 mg/g之间，丹参酮测定在0.49-0.57 mg/g之间</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >6，7】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。然而很少有关于消癖颗粒吸收物质的报道，而消癖颗粒在体内可能的代谢途径尚不清楚。因此系统地分析其吸收物质及其作用靶点，对于解释其药理作用和物质基础具有重要意义和必要性。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >众所周知，中药配方通常含有上千种化学物质，多种化合物之间存在复杂的相互作用，如何识别可吸收物质是药理学家面临的一大挑战。在过去的十年中，网络药理学已成为建立化合物</font><font face="宋体" >-化合物、靶标-疾病和化合物-靶标之间系统相关性的新工具</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >8，9】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。随着化合物收集、药代动力学评价</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >(吸收、分布和代谢)、靶标预测和网络分析，预测整个药物-靶标相互作用网络和确定相关核心分子和途径变得越来越快、越来越容易</span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >0</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。网络药理学使我们有机会将药理学研究策略从</font><font face="宋体" >“一药一靶”模式转变为“药-靶网络相互作用”模式</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >1</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。通过该方法，我们对消癖颗粒的</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >10个中草药共产生</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >的</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >105个成分</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >和</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >806个潜在靶标进行了筛选。更重要的是，通过与乳腺癌GENECARDS数据库和GSE5764微阵列杂交，最终鉴定出81个乳腺癌相关基因为用药后的潜在靶标</span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >5】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。但由于方法上的限制，我们只能从不同的数据库中收集化合物和靶标来建立化合物</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >-靶标图。在此过程中，也考虑到一些生物利用度低的物质，不可避免地导致假阳性结果。因此，可吸收成分的检测对于成功预测潜在化合物目标网络是非常必要的。</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >最近，高效液相色谱与质谱联用</font><font face="宋体" >(LC-MS) 方法越来越多地用于生物样品分析，具有高灵敏度和高通量的优势</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >&nbsp;<font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >2</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >，</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >3</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。在这项工作中，我们使用</font> <font face="宋体" >UPLC 结合高分辨率 MS对消癖颗粒的吸收原型成分和代谢物进行了表征。此外，利用网络药理学将吸收的成分与相应的靶标整合，并产生潜在的代谢途径。就我们而言，这是首次揭示消癖颗粒在体内吸收物质、代谢途径和靶点药理网络分析的综合结果。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" >2</span></b><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >.</font><font face="宋体" >材料和方法</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >消癖颗粒的制备</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >消癖颗粒提取物样品（</font><font face="宋体" >20mg）加入1000&#956;</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >L</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >溶剂（乙腈</font><font face="宋体" >-甲醇-水：2:2:1，含有1&#956;g/mL的L-2-氯苯丙氨酸）并涡旋振荡30s，在45Hz下匀质4分钟，然后在冰水浴中超声5分钟。匀质和超声循环重复3次。然后将混合物以12,000rpm离心15分钟。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >最后，将</font><font face="宋体" >2&#956;L处理过的样品上清液注入LC-MS/MS检测系统。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >2 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >动物实验</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >十二只雌性</font> <font face="宋体" >Sprague-Dawley(SD)大鼠购自广东省实验动物有限公司（中国广东）。大鼠在温度为24&#177;2℃、湿度为55&#177;15％、暗光周期为1</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >h的条件下适应一周。实验前，所有大鼠禁食过夜，自由饮水。雌性SD大鼠12只，体重200&#177;10g，随机分为2组，一次灌胃给予水提物（6g/kg）或等量生理盐水。分别在给药前和给药后60分钟，用肝素化管中从眼睛中收集约1mL血样。血样以4000rpm离心15分钟后分离血清，并储存于-80℃以备后用。所有动物护理和实验步骤均按照广州中医药大学动物伦理评审委员会批准的方案进行。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >3 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >代谢物提取</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >每</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >100&#956;L血清样品与300&#956;L甲醇（含有1&#956;g/mL的L-2-氯苯丙氨酸）混合，涡旋60秒，在冰水浴中超声</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >处理</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >5分钟以沉淀蛋白质</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >在</font>4&#176;C下以12,000rpm 离心15分钟后，将2&#956;L处理过的样品上清液注入</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >超高效液相色谱－四极杆</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >/静电场轨道阱高分辨质谱</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >（</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >UPLC-Q-Orbitrap MS</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >）</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >检测系统。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >.4 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >超高效液相色谱－四极杆</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >/静电场轨道阱高分辨质谱</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >UPLC-Q-Orbitrap质谱分析是使用UHPLC系统（1290，安捷伦科技公司），UPLC HSS T3 色谱柱（2.1mm×100mm，1.8</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >&#956;</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >m，Waters）与Q Exactive Orbitrap（QE，Thermo Fisher Scientific，美国）耦合进行的。流动相A为0.1%甲酸水溶液为阳性，5mmol/L醋酸铵水溶液为阴性，流动相B为乙腈。洗脱梯度设置如下：0分钟，1%B；1分钟，1%B；8分钟，99%B；10分钟，99%B；10.1分钟，1%B；12分钟，1%B。流速为0.5mL/min。进样体积为2</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >&#956;</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >L。QE质谱仪因其能够在LC/MS实验期间基于信息依赖性(IDA)获取MS/MS谱图而被使用。在此模式下，采集软件(Xcalibur 4.0.27,Thermo) 根据预先选定的标准，在采集和触发M</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >S/MS</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >光谱时，持续评估全扫描测量</font><font face="宋体" >MS数据。ESI源条件设置如下：鞘气流速为45Arb，辅助气流速为15Arb，毛细管温度320℃，在NCE模型中全质量分辨率为70000，MS/MS分辨率为17500，碰撞能量为20/40/60eV，喷雾电压分别为3.8kV（正）或-3.1kV（负）。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.5</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >数据处理和差异代谢物分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >对于外源性成分，通过使用</font><font face="宋体" >QE结合Compound Discover2.0和Xcalibur 4.0.27的数据分析，采用了化学代谢物检测和结构解析的通用策略。在全扫描模式下采集样品的MS数据，并通过动态排除设置执行数据相关的MS</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >n</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >扫描。比较处理样品和空白样品的总离子色谱图</font><font face="宋体" >(TIC)，筛选出可能的原型成分和代谢物，排除内源性成分。随后，将通过LC-MS/MS检测的消癖颗粒的化学特征与血清中的差异物质杂交，然后给药。对于内源性代谢物，仅选取两组之间在方差分析中有显著变化（p值&lt;0.05和VIP（变量重要性指标）值≥1.0）的差异代谢物作为潜在的生物标志物，并进一步鉴定KEGG通路和分子机制。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >6 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >K</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >EGG</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >通路分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >KEGG是主要的公共通路相关数据库，不仅包括基因，还包括代谢物。代谢物被映射到KEGG代谢途径以进行途径分析和富集分析。通路富集分析确定了与整个背景相比，差异代谢物中显著富集的代谢通路或信号转导通路。计算公式如下：</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:center;line-height:150%;" ><img width="293"  height="105"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03263833.png" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >这里</font><font face="宋体" >N是所有带有KEGG标注的代谢物的数量，n是N中差异代谢物的数量，M是所有带有特定途径标注的代谢物的数量，m是M中差异代谢物的数量。 计算出的p值经过FDR校正，以P≤0.05作为阈值。满足此条件的途径被定义为差异代谢物的显著富集途径。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="mso-pagination:widow-orphan;text-align:left;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >7 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >细胞培养和药物干预</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >将来自江苏凯基生物技术股份有限公司（货号：</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >KG063）的人乳腺癌细胞系LO2维持在含有10%FBS和1%青霉素和链霉素（Gibco Life Technologies，Lofer，Austria）的RPMI1640培养基中，</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >培养基放置于</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >温度</font>37</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >℃，</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >含</font>5%CO</span><sub><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:sub;" >2</span></sub><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >的加湿培养箱中。将</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >粉末溶解在蒸馏水中，并以指定的浓度和持续时间加入细胞培养系统中。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >8 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >蛋白质印迹法</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >为了确定蛋白质浓度，将细胞在含有蛋白酶抑制剂混合物（</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >Roche Diagnostics，IN）的RIPA缓冲液（Sigma，St. Louis，MO）中裂解。用二辛可宁酸法（Thermo Fisher Scientific，波恩，德国）测</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >定</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >蛋白质浓度。对定量的蛋白质裂解物</font>(30</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >&#956;</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >g)进行十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，并在</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >10%聚丙烯酰胺凝胶上溶解。然后将蛋白质转移到PVDF膜（GE Healthcare，Freiburg，Germany）上。膜用CYP7A1的一抗（Bioss，北京，中国）在4</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >下探测过夜。用</font>Tris缓冲盐水和0.05%</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >吐温</font><font face="宋体" >2</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >（</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >Tween-20</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >）</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >洗涤</font>3次后，将膜与二级抗兔（Cell Signaling Technology，Beverly，MA，USA）在室温下孵育2小时。使用ECL Advance试剂（GE Healthcare）对信号进行可视化，并使用Image J软</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >件进行量化。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >2.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >9 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >免疫荧光分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >为了检测</font><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >YP7A1</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >的表达，无论是否加入消癖颗粒，将大鼠冰冻肝组织切片</font><font face="宋体" >8&#956;</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >m，在固定</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >前</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >在长凳上干燥几分钟。将</font>4%多聚甲醛施用于切片15分钟。在山羊血清封闭60分钟后，将样品与一抗CYP7A1在4</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >下共孵育过夜，然后在室温下用荧光偶联的二抗标记</font>1小时。最后应用4,6二脒基-2-苯基吲哚（DAPI）进行核染色，并用NIKON TS2R荧光显微镜检测信号。</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="mso-pagination:widow-orphan;text-align:left;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><br clear=all style='page-break-before:always'></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >3</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" >&nbsp;</span></b><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >结果</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >1 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >UPLC-Q-Orbitrap MS数据处理与分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><img width="554"  height="532"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03264804.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >图</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:233.8500pt;
mso-para-margin-left:22.2700gd;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >(a)</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >提取物的总离子</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >色谱</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >图；</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:233.8500pt;
mso-para-margin-left:22.2700gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >(b)口服</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >治疗前后血清中检测成分的总离子色谱图（阳性或阴性模式）；</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:233.8500pt;
mso-para-margin-left:22.2700gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >(c)</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >成分（红色）和</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >血清成分（绿色）分别在阳性或阴性模式下的维恩</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >图</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >结果。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >消癖颗粒提取物的总色谱图见图</font><font face="宋体" >1a。通过LC-MS/MS检测，消癖颗粒处理前后血清的基峰色谱图见图1b。使用Proteo Wizard将MS原始数据文件转换为mzML格式，并通过R package XCMS（版本3.2）进行处理，包括保留时间对齐、峰检测和峰匹配。OSI-SMMS（1.0版，大连化学数据解决方案信息技术有限公司）使用内部MS/MS数据库用于进行峰注释。为了分析消癖颗粒的可吸收成分，首先选择空白血清和消癖颗粒处理后的血清的差异化学特征，来筛选通过串联质谱法验证的物质。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="text-align:center;" ><img width="599"  height="663"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03265154.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.1000pt;
text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >表</font><font face="等线" >1 血清中原型成分及代谢物鉴定结果</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >结果表明，通过比较空白组和消癖颗粒处理组，共过滤出</font><font face="宋体" >123种正离子（POS）化学物质和73种负离子（NEG）化学物质。有趣的是，在消癖颗粒中发现了115种阳性化学物质和61种阴性化学物质（图 1</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >c</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >）。在这些发现的化学物质中，确定了</font><font face="宋体" >38种阳性和25种阴性（表1），而剩下的化学物质被标记为未知。对于MS表征，m/z249和193处的诊断离子可用于快速提取和鉴定丹参酮I相关代谢物。同样，m/z277和249处的离子被鉴定为用于丹参酮II相关代谢物结构解析的诊断片段。例如，M22 在m/z</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >297.1477处显示出准分子离子[M-H]</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >+</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >，而</font><font face="宋体" >MS</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >2</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >产物离子在</font><font face="宋体" >m/z 277和 249处，这也比丹参酮II高2Da（道尔顿）。因此，M22被初步鉴定为隐丹参酮。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="mso-pagination:widow-orphan;text-align:left;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >.</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >2 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >丹参酮相关代谢物的代谢途径分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><img width="554"  height="560"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03265523.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >图</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >&nbsp;2</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:21.0000pt;
mso-char-indent-count:2.0000;text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >a）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >血清中丹参酮</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >&#8544;</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >的代谢途径；（</font>b</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >血清中丹参酮</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >&#8545;</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >的代谢途径。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >在消癖颗粒处理血清中鉴定出的</font><font face="宋体" >63种化合物中，丹参酮类化合物占24种，相对百分比为38.09%（表1），远高于其他物质的百分比。因此，丹参酮相关代谢物被认为是体内的主要代谢物，包括10种丹参酮I相关代谢物（M2、M4、M8、M9、M13、M14、M20-21、M39 和 M40）和14种丹参酮II相关代谢物（M15-19、M22-24、M26-29、M43 和 M54）。结果表明丹参酮&#8544;在血清中主要发生羟基化（M2）、脱水（M4）、硫酸化（M8-9、M13-14、M21）、水化（M39）、氢化（M40）和脱氢（M20），而在丹参酮II的代谢物中观察到羟基化（M16-19、M23、M54）、硫酸化（M43）、氢化（M22、M26-28）、脱氢（M24）、甲基化(M15)和葡萄糖醛酸化(M29)。同时，前20种增加物质的结果（表2）揭示了5种丹参酮II相关代谢物和4种丹参酮I相关代谢物的参与。因此，推测的大鼠血清中丹参酮I和丹参酮II的代谢途径如图2a和图2b所示。通过分析丹参酮&#8544;和丹参酮&#8545;的代谢产物，发现丹参酮&#8544;的D环更不稳定，容易通过各种代谢酶的反应失去一分子CO和一分子CH3，而丹参酮&#8545;则不是这样。由于不饱和A环，丹参酮II容易发生加氢反应，进而形成稳定的&#960;-&#960;共轭体系，生成其他代谢物。总的来说，研究结果表明丹参酮相关代谢途径可用于消癖颗粒的质量控制。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="text-align:center;" ><img width="555"  height="248"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03266149.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.1000pt;
text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >表</font> <font face="等线" >2</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >血清中已鉴定成分的</font> <font face="等线" >Top 20</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=MsoNormal  style="mso-pagination:widow-orphan;text-align:left;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><br clear=all style='page-break-before:always'></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >3.3.通过代谢组学分析对差异代谢物进行KEGG分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><img width="554"  height="497"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03266202.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >图</font><font face="宋体" >3</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >a）口服消癖颗粒后血清中所有成分的热图（阳性模式）；</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >b）口服消癖颗粒后血清中所有成分的热图（阴性模式）；</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >c）消癖颗粒治疗前后大鼠血清中所有成分的P</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >CA</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >分析；</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >d）前2</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >个干扰了所有成分的</font><font face="等线" >K</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >EGG</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >通路。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >为了找到具有显著变化的内源性代谢物，我们将变化阈值设置为</font><font face="宋体" >[log2FC]&gt; 1。根据预测中的变量重要性指标(VIP)分数对最能区分两组的代谢物进行排序。POS和NEG中所有不同内源性代谢物的热图统计数据分别显示在图3a和图3b中。主成分分析（PCA）进一步显示，空白组和消癖颗粒组的图谱是独立聚类的，表明消癖颗粒给药后大鼠血清中的成分发生显著变化（图3c）。KEGG通路注释分析表明，所有内源性代谢物对氨基酸代谢(216)、碳水化合物代谢(228)和核苷酸代谢(123)都有很大影响（图3d）。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="mso-pagination:widow-orphan;text-align:left;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><br clear=all style='page-break-before:always'></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >筛选结果显示，</font><font face="宋体" >POS中共有1142种代谢物上调，775种化学物质下调，而NEG中911种代谢物增加，442种化学物质下调（图4a）。差异物质统计数据如图4b所示。KEGG分析表明，受干扰的通路包括112个信号通路，前20个通路见表3和图4c。主要的途径包括胆汁分泌（P=0.001534）、萜类骨干生物合成（P=0.010400）、初级胆汁酸生物合成（P=0.025424）和甲状腺激素信号传导（P=0.028516）（图4d）。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><img width="555"  height="252"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03266780.png" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:21.0000pt;
text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >表</font><font face="宋体" >3消癖颗粒处理后差异代谢物改变的前20条通路。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="text-align:justify;text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >1 胆汁分泌；2 萜类骨架生物合成；3 初级胆汁酸生物合成；4 甲状腺激素信号通路；5 卟啉和叶绿素代谢；6 血管平滑肌收缩；7 间隙连接；8 长期抑制；9 逆行内源性大麻素信号；10 抗生素的生物合成；11 PPAR 信号通路；12 光转导；13 胰岛素信号通路；14 GnRH 信号通路；15 碳水化合物消化和吸收；16 代谢通路；17 糖基磷脂酰肌醇 (GPI)-锚生物合成；18 自噬调节；19 淀粉和蔗糖代谢；20 血小板活化；</font></span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><img width="554"  height="573"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03267028.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >图</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >&nbsp;4</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-indent:21.0000pt;mso-char-indent-count:2.0000;
text-align:justify;text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >(a) 正负模式下所有不同内源代谢物的柱状统计数据；</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-indent:21.0000pt;mso-char-indent-count:2.0000;
text-align:justify;text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >(b) 正负模式下所有不同内源性代谢物的热图；</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-indent:21.0000pt;mso-char-indent-count:2.0000;
text-align:justify;text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >(c) 所有不同内源性代谢物的前20个干扰KEGG途径；</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:326.0000pt;
mso-para-margin-left:31.0500gd;text-indent:21.0000pt;mso-char-indent-count:2.0000;
text-align:justify;text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" >(d) 所有不同内源性代谢物的KEGG通路富集分析。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="mso-pagination:widow-orphan;text-align:left;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><br clear=all style='page-break-before:always'></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >3.4.消癖颗粒对胆汁酸代谢途径的影响</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><img width="482"  height="449"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03267163.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >图</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >5.</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >对初级胆汁酸生物合成的可能机制。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >说明</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >对胆汁酸生物合成的调控作用可能与关键酶</font>CYP7A1有关。</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >根据代谢研究结果，胆汁酸代谢途径被认为是消癖颗粒干预的主要信号通路。关于参考途径，表明胆酸、甘氨胆酸、牛磺鹅去氧胆酸和牛磺胆酸的合成是该途径的关键点（蓝色突出显示，图</font><font face="宋体" >5）。定量分析还显示，消癖颗粒处理后血清中所有四种物质的含量水平均显著提高（图6a）。由于胆固醇7α-羟化酶 (CYP7A1) 是胆汁酸合成的关键酶（白色突出显示，图5），我们随后在消癖颗粒给药后检测了其在大鼠肝组织中的表达。结果表明，消癖颗粒在免疫印迹和免疫组织化学分析中均显著增强了CYP7A1的表达（图6b-c）。体外实验还表明，消癖颗粒能以时间和剂量依赖性方式显著增加人正常肝细胞LO2细胞系中CYP7A1的表达（图6d），提示C</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >YP7A1</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >可能是调节消癖颗粒药物生物活性的关键酶之一。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:center;
line-height:150%;" ><img width="554"  height="474"  src="5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略0326.files/5、中药消癖颗粒代谢产物分析：基于UPLC-Q-Orbitrap MS结合网络药理学分析的综合策略03267554.png" ><span style="mso-spacerun:'yes';font-family:宋体;color:rgb(102,102,102);
font-size:12.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=center  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >图</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >&nbsp;6 </span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >对胆汁酸代谢途径的影响。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:240.9500pt;
mso-para-margin-left:22.9500gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >a）消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >治疗后血清中胆酸、甘氨胆酸、牛磺鹅去氧胆酸和牛磺胆酸水平</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >显著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >升高；</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:240.9500pt;
mso-para-margin-left:22.9500gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >b）-（c）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >大鼠模型在</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >治疗前后</font>CYP7A1表达的免疫印迹和免疫荧光分析；</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;margin-left:240.9500pt;
mso-para-margin-left:22.9500gd;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >（</font><font face="等线" >d）在</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >指定浓度和持续时间</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >下，用</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >蛋白质印迹分析</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >经消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><font face="等线" >处理的人正常肝细胞</font>LO2细胞系中CYP7A1的表达。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:宋体;
line-height:150%;font-size:10.5000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >4.</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" >&nbsp;</span></b><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >讨论</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >在过去的十年中，包括基因组学、转录组学和蛋白质组学在内的多组学技术，已被开发用于高通量筛选和鉴定中药配方中涉及的靶点</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >[14]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。尽管在解释中药的分子机制方面取得了很大进展，但阐明可吸收物质并建立化合物</font><font face="宋体" >-靶点相关性仍然是一个巨大的挑战。代谢组学作为组学家族的一员，可以为生物体中发生的事情提供新的见解。目前，在代谢组学研究中识别和量化小分子的常规分析方法，要么基于核磁共振波谱，要么基于质谱。质谱技术与液相色谱相结合，为后续的通路分析和目标识别提供了大量的化学信息。特别是，超高液相色谱-质谱系统联用已被视为表征复杂生物样品中全局代谢特征的主要工具之一，并广泛应用于中药研究</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >&nbsp;<font face="宋体" >[15，16]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。例如，据报道，</font><font face="宋体" >Zhu等人，通过使用超高液相色谱-质谱分析，黄连解毒汤通过协调代谢应激、谷氨酸代谢和乙酰胆碱水平的网络达到治疗作用</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >[17]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。同样，张等人，通过使用液质联用技术，共鉴定出</font><font face="宋体" >PHY906配方中的57种化合物和27种代谢物。然而，液相</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >-质谱分析中吸收物质的鉴定却很少受到重视</span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >8</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >通过将消癖颗粒的质谱与大鼠血清中发现的化学物质进行交叉，共检测到</font> <font face="宋体" >196种化合物，并作为相关成分进行过滤。在这些化学物质中，已知38种为阳性和25种为阴性，包括40种代谢物和23种原始化合物。在充分理解裂解规律和母体化合物特征产物的基础上，对不同代谢途径形成的代谢物类型进行了表征。通常，体内代谢包含例如氧化、还原、水解和结合反应等&#8544;相和&#8545;相转化。在本研究中观察到羟基化(16Da)、甲基化(14Da)、氢化(2Da)、葡萄糖醛酸化(176Da) 和硫酸化(80Da)。代谢物的鉴定是通过比较代谢物的分子(&#9651;M)和MS</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >2</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >光谱模式与母体化合物的变化来进行的</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >&nbsp;<font face="宋体" >[19，20]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。在我们的研究中，结果表明丹参酮</font><font face="宋体" >II和丹参酮I的途径是主要的代谢途径。一些证据表明，丹参酮II减弱了乳腺癌干细胞的活性</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >[21-27]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。同时，丹参酮</font><font face="宋体" >I也是被证明可以诱导乳腺癌的抗增殖活性和细胞周期停滞</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >&nbsp;<font face="宋体" >[28,29]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。由于丹参是消癖颗粒中的主要草药，丹参酮可以被认为是配方质量控制的主要化学标准。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >对于内源性代谢物分析，通路富集分析最终显示胆汁酸分泌信号受到最显著的影响。在上调的物质中，胆酸、甘氨胆酸、牛磺鹅脱氧胆酸和牛磺胆酸的含量水平均被上调。同时</font><font face="宋体" >CYP7A1酶的表达也显著增加，说明消癖颗粒可加速胆汁酸代谢。据报道，胆汁酸水平的增加有利于乳腺癌的治疗。卢等人，发现石胆酸通过显著减少细胞内的脂滴和ERα的表达，对MCF-7和MDA-MB-231细胞具有抗增殖和促凋亡作用</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" >&nbsp;<font face="宋体" >[30]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >另一项研究报告称，胆汁酸为他莫昔芬的负载提供了新的支架，与母体药物他莫昔芬相比，胆酸</font><font face="宋体" >-他莫昔芬缀合物被认为是最有效的抗癌组合物</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >[31]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。同时，许多胆汁酸衍生物也通过</font><font face="宋体" >p</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >53</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >非依赖性途径在人乳腺癌细胞中表现出诱导凋亡作用</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;vertical-align:super;" ><font face="宋体" >[32]</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >。所有这些发现都表明胆汁酸的合成可能是影响消癖颗粒抗癌活性的一个重要因素。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" >5</span></b><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >.</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" >&nbsp;</span></b><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >结论</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >综上所述，我们的结果清晰地展示了消癖颗粒在体内的代谢途径，不仅提供了吸收的成分，还突出了胆汁酸合成途径在介导消癖颗粒药理活性中的潜在关键作用。更重要的是，液质联用</font><font face="宋体" >-网络药理学的应用将为未来揭示中药的潜在靶点和生物加工机制提供更可靠、更令人信服的方法。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >利益冲突</font> </span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >作者声明他们没有利益冲突。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >补充材料</font></span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >与本文相关的补充材料可在在线版本</font><font face="宋体" >doi中找到：https://doi.org/10.1016/j.biopha.2019.109569。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >基金</font></span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;text-align:justify;text-justify:inter-ideograph;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >这项工作得到了国家自然科学基金（</font><font face="宋体" >81573651、81873306、81973526、81703764和81703749），广东省科技厅（2016A030306025），广东省特殊支持计划高层次人才（</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >A1-3002</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >-</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >16</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >-</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >111</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >-</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >003</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >）</font><font face="宋体" >, 广东省教育厅(2018KZDXM022 和A1-2606-19-111-009), 广东省中医药局(20181132 和 20182044), 广东省自然科学基金博士启动基金（2017A030310213和2018A030310506），广东省科技计划项目（2017B030314166），广州市科技项目（201904010407），广东省中医院中医药科技专项研究基金（YN207QN2018M</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >J07</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >和</font><font face="宋体" >Y</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" >N2018QJ08</span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><font face="宋体" >）的支持。</font></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="mso-pagination:widow-orphan;text-align:left;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><br clear=all style='page-break-before:always'></span><span style="mso-spacerun:'yes';font-family:宋体;font-size:12.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=p  align=justify  style="margin-top:0.0000pt;margin-bottom:0.0000pt;text-align:justify;
text-justify:inter-ideograph;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >参考文献</font></span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >H.-L. Situ, Q.-j. Chen, The clinical research of "Xiaopi" oral liquids in reversing precancerosis of breast and affecting the secretion of E2 and P in Luteal Phase, Chinese Journal of Cancer Prevention and Treatment 9 (2) (2002) 176–178.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >X. Meng, D. Shou, L. Chen, The effects of Xiaopi Granules on the mastoplasia model</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >of rats, Pharmacology and Clinics of Chinese Materia Medica 21 (1) (2005) 34–35.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >J. Chen, B.-w. LI, X.-b. MENG, D.-w. SHOU, The effects of Xiaopi Granules on of the</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >rabbit mastoplasia model, Qilu Pharmaceutical Affairs 26 (7) (2007) 427–428.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Q.-j. Chen, B. Xu, H.-l. Situ, Y. Dai, R.-d. Guan, Y. Lin, The effect of“xiaopi granule</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >”</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >on the SD rate pre-cancerosis models and on the pathway of EGFR-STAT3,</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Journal of Liaoning University of Traditional Chinese Medicine 14 (8) (2012)19–21.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >N. Wang, Y. Zheng, J. Gu, Y. Cai, S. Wang, F. Zhang, J. Chen, H. Situ, Y. Lin,Z. Wang, Network-pharmacology-based validation of TAMS/CXCL-1 as key mediator of XIAOPI formula preventing breast cancer development and metastasis, Sci.Rep. 7 (1) (2017) 14513.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >6】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >H. Liu, Study on determination of Xiaopi Granules by HPLC, China Medical herald 7(27) (2010) 47–50.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >7】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >D. Wang, N. Huang, Determination of tanshinone in Xiaopi Granules by TLC, Guangzhou Medical Journal 41 (5) (2010) 59–60.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >8】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >T.T. Luo, Y. Lu, S.K. Yan, X. Xiao, X.L. Rong, J. Guo, Network pharmacology in</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >research of chinese medicine formula: methodology, application and prospective, Chinese journal of integrative medicine undefined (2019) undefined.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >9】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >S. Li, B. Zhang, Traditional Chinese medicine network pharmacology: theory,</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >methodology and application, Chin. J. Nat. Med. 11 (2) (2013) 110–120.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >H. Liu, J. Wang, W. Zhou, Y. Wang, L. Yang, Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice,J. Ethnopharmacol. 146 (3) (2013) 773–793.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >G.B. Zhang, Q.Y. Li, Q.L. Chen, S.B. Su, Network pharmacology: a new approach for</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >chinese herbal medicine research, Evid. Complement. Alternat. Med. 2013 (2013)621423.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >M. Xu, Z. Xu, Q. Xu, H. Zhang, M. Liu, F. Geng, N. Zhang, UPLC-MS/MS method for</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >the determination of 14 compounds in rat plasma and its application in a pharmacokinetic study of orally administered xiaoyao powder, Molecules 23 (10) (2018) undefined..</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Q. Zhai, J. Pang, G. Li, C. Li, X. Yang, L. Yu, Y. Wang, J. Li, X. You, Validated LC–MS/MS method for determination of YH-8, a novel PKnB inhibitor, in rat plasma</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >and its application to pharmacokinetic study, Acta Pharm. Sin. B 5 (5) (2015)467–472.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >4</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >T. Xu, Z. Pi, S. Liu, F. Song, Z. Liu, Chemical profiling combined with "Omics"</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >technologies (CP-Omics): a strategy to understand the compatibility mechanisms</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >and simplify herb formulas in traditional chinese medicines, Phytochem. Anal. 28(5) (2017) 381–391.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >5</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Y.Y. Zhao, R.C. Lin, UPLC-MS(E) application in disease biomarker discovery: the</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >discoveries in proteomics to metabolomics, Chem. Biol. Interact. 215 (undefined)(2014) 7–16.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >I.D. Wilson, R. Plumb, J. Granger, H. Major, R. Williams, E.M. Lenz, HPLC-MS-based</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >methods for the study of metabonomics, Journal of chromatography. B, Analytical</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >technologies in the biomedical and life sciences 817 (1) (2005) 67–76.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >B. Zhu, H. Cao, L. Sun, B. Li, L. Guo, J. Duan, H. Zhu, Q. Zhang, Metabolomics-based</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >mechanisms exploration of Huang-Lian Jie-Du decoction on cerebral ischemia via</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >UPLC-Q-TOF/MS analysis on rat serum, J. Ethnopharmacol. 216 (2018) 147–156.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >8</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;W. Zhang, M.W. Saif, G.E. Dutschman, X. Li, W. Lam, S. Bussom, Z. Jiang, M. Ye,</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >E. Chu, Y.C. Cheng, Identification of chemicals and their metabolites from PHY906,</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >a Chinese medicine formulation, in the plasma of a patient treated with irinotecan</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS), J. Chromatogr. A 1217 (37) (2010) 5785–5793.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >9</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;H. Ma, Y. Liu, X. Mai, Y. Liao, K. Zhang, B. Liu, X. Xie, Q. Du, Identification of the</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >constituents and metabolites in rat plasma after oral administration of</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >HuanglianShangqing pills by ultra high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry, J. Pharm. Biomed. Anal. 125 (2016)194–204.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Z.F. Qin, Y. Dai, Z.H. Yao, L.L. He, Q.Y. Wang, J.L. Geng, H.F. Chen, X.S. Yao, Study</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >on chemical profiles and metabolites of Allii Macrostemonis Bulbus as well as its representative steroidal saponins in rats by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry, Food</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Chem. 192 (2016) 499–515.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >S. Gao, Z. Liu, H. Li, P.J. Little, P. Liu, S. Xu, Cardiovascular actions and therapeutic</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >potential of tanshinone IIA, Atherosclerosis 220 (1) (2012) 3–10.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;K. Li, W. Liu, Q. Zhao, C. Wu, C. Fan, H. Lai, S. Li, Combination of tanshinone IIA</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >and doxorubicin possesses synergism and attenuation effects on doxorubicin in the</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >treatment of breast cancer, Phytother. Res. 33 (6) (2019) 1658–1669.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >H. Lin, L. Zheng, S. Li, B. Xie, B. Cui, A. Xia, Z. Lin, P. Zhou, Cytotoxicity of</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >through inhibition of Tau, Phytother. Res. 32 (4) (2018) 667–671.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >4</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >S. He, M. Wang, Y. Zhang, J. Luo, Monitoring the early response of fulvestrant plus</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >tanshinone IIA combination therapy to estrogen receptor-positive breast Cancer by</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >longitudinal (18)F-FES PET/CT, Contrast Media Mol. Imaging (2019) (2019)2374565.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >5</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >C. Lin, L. Wang, H. Wang, L. Yang, H. Guo, X. Wang, Tanshinone IIA inhibits breast</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways, J. Cell. Biochem. 114 (9) (2013) 2061–2070.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >P. Fu, F. Du, W. Chen, M. Yao, K. Lv, Y. Liu, Tanshinone IIA blocks epithelialmesenchymal transition through HIF-1alpha downregulation, reversing hypoxiainduced chemotherapy resistance in breast cancer cell lines, Oncol. Rep. 31 (6)(2014) 2561–2568.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >G. Li, C. Shan, L. Liu, T. Zhou, J. Zhou, X. Hu, Y. Chen, H. Cui, N. Gao, Tanshinone</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >IIA inhibits HIF-1alpha and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway, PLoS One 10 (2) (2015) e0117440.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >8</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >L. Wang, J. Wu, J. Lu, R. Ma, D. Sun, J. Tang, Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines,Mol. Med. Rep. 11 (2) (2015) 931–939.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >9</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >M. Lu, C. Wang, J. Wang, Tanshinone I induces human colorectal cancer cell</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >apoptosis: the potential roles of Aurora A-p53 and survivin-mediated signaling</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >pathways, Int. J. Oncol. 49 (2) (2016) 603–610.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >T.H. Luu, J.M. Bard, D. Carbonnelle, C. Chaillou, J.M. Huvelin, C. Bobin-Dubigeon,</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >H. Nazih, Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >cancer cells, Cell. Oncol. Dordr. (Dordr) 41 (1) (2018) 13–24.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >V. Sreekanth, S. Bansal, R.K. Motiani, S. Kundu, S.K. Muppu, T.D. Majumdar, K. Panjamurthy, S. Sengupta, A. Bajaj, Design, synthesis, and mechanistic investigations of bile acid-tamoxifen conjugates for breast cancer therapy, Bioconjug.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Chem. 24 (9) (2013) 1468–1484.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >E.O. Im, Y.H. Choi, K.J. Paik, H. Suh, Y. Jin, K.W. Kim, Y.H. Yoo, N.D. Kim, Novel</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >bile acid derivatives induce apoptosis via a p53-independent pathway in human</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >breast carcinoma cells, Cancer Lett. 163 (1) (2001) 83–93.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p>&nbsp;</o:p></span></p></div><!--EndFragment--></body></html>